Skip to main content

Table 2 Baseline risk factors for death or hepatocellular carcinoma among HBV-infected patients who started antiviral therapy

From: Five-year results of a treatment program for chronic hepatitis B in Ethiopia

 

Total

(n = 291)

Deceaseda

(n = 53)

Crude hazard ratio

(95% CI)

Significance

(p)

Adjusted hazard ratio (95% CI)

Significance

(p)

Baseline variables

Sex (female vs. male)

 Male

223 (76.6)

44 (83.0)

1

   

 Female

68 (23.4)

9 (17.0)

0.6 (0.3–1.3)

0.237

NA

NA

Age (vs. < 30 years)

 18–29

98 (33.7)

7 (13.2)

1

 

1

 

 30–39

103 (35.4)

16 (30.2)

2.3 (0.9–5.5)

0.069

1.5 (0.6–3.6)

0.404

  ≥ 40

90 (30.9)

30 (56.6)

5.1 (2.2–11.5)

 < 0.001

3.7 (1.6–8.5)

0.002

Alcohol misuse (vs. no misuse)

 No

270 (92.8)

49 (92.5)

1

   

 Yes

21 (7.2)

4 (7.5)

1.1 (0.4–3.0)

0.860

NA

NA

ALT (vs. < 40 IU/L)

  < 40

166 (57.0)

31 (58.5)

1

   

 40–79

86 (29.6)

14 (26.4)

1.0 (0.5–1.8)

0.896

NA

NA

  ≥ 80

39 (13.4)

8 (15.1)

1.2 (0.6–2.6)

0.647

NA

NA

HBV DNA viral load (vs. < 2000 IU/mL)

  < 2000

91 (31.3)

21 (39.6)

1

 

1

 

 2000–20,000

47 (16.2)

5 (9.4)

0.5 (0.2–1.3)

0.165

0.9 (0.3–2.4)

0.795

  > 20,000

153 (52.6)

27 (50.9)

0.8 (0.5–1.4)

0.456

1.2 (0.7–2.1)

0.626

HBeAg status (positive vs. negative)b

 Negative

202 (70.4)

40 (75.5)

1

   

 Positive

85 (29.6)

13 (24.5)

0.7 (0.4–1.4)

0.316

NA

NA

Transient elastography (vs. < 8.0 kPa)c

  < 8.0

59 (21.4)

1 (2.0)

1

   

 8.0–9.9

39 (14.1)

1 (2.0)

1.6 (0.1–25.3)

0.745

NAd

NAd

  ≥ 10.0

178 (64.5)

47 (95.9)

16.6 (2.3–120.5)

0.005

NAd

NAd

Cirrhosis status (vs. no cirrhosis):

 No cirrhosis

103 (35.4)

1 (1.9)

1

 

1

 

 Compensated cirrhosis

83 (28.5)

8 (15.1)

9.0 (1.1–72.3)

0.038

7.2 (0.9–58.6)

0.065

 Decompensated cirrhosis

105 (36.1)

44 (83.0)

52.2 (7.2–379.3)

 < 0.001

44.6 (6.1–328.1)

 < 0.001

  1. Data are presented as number (%)
  2. aEight patients developed hepatocellular carcinoma and were registered as deceased in the survival analysis due to the poor prognosis in sub-Saharan Africa [19]
  3. bHBeAg status was missing in four patients, of whom none died or developed hepatocellular carcinoma
  4. cTransient elastography was missing in 15 patients, of whom three died and one developed hepatocellular carcinoma
  5. dTransient elastography could not be included in the adjusted model because of a strong correlation with one of the other variables